U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to ...
Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy: New York Saturday, October 11, 2025, 16: ...
Pharmaceutical companies should look afresh at the business case for investing in ‘candidate’ biosimilars amidst signs that ...
Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven ...
Stocktwits on MSN
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process
Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the ...
TipRanks on MSN
Lexeo Therapeutics reports on LX2006 approval pathway
Lexeo Therapeutics (LXEO) announced updates to key components of an Accelerated Approval pathway for LX2006 in Friedreich ataxia, or FA, ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
A physician who heads the influential U.S. Food and Drug Administration vaccine advisory committee recused herself from the panel's review of COVID-19 vaccines because of her role overseeing a ...
The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.
Biomea Fusion's experimental drug showed sustained blood sugar control in patients with type 2 diabetes and may benefit those not responding to GLP-1 therapies like Novo Nordisk's Ozempic, it said on ...
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback